Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 11:14:3235-3249.
doi: 10.2147/DDDT.S257494. eCollection 2020.

Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases

Affiliations
Review

Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases

Xolani H Makhoba et al. Drug Des Devel Ther. .

Abstract

It is essential to acknowledge the efforts made thus far to manage or eliminate various disease burden faced by humankind. However, the rising global trends of the so-called incurable diseases continue to put pressure on Pharma industries and other drug discovery platforms. In the past, drugs with more than one target were deemed as undesirable options with interest being on the one-drug-single target. Despite the successes of the single-target drugs, it is currently beyond doubt that these drugs have limited efficacy against complex diseases in which the pathogenesis is dependent on a set of biochemical events and several bioreceptors operating concomitantly. Different approaches have thus been proposed to come up with effective drugs to combat even the complex diseases. In the past, the focus was on producing drugs from screening plant compounds; today, we talk about combination therapy and multi-targeting drugs. The multi-target drugs have recently attracted much attention as promising tools to fight against most challenging diseases, and thus a new research focus area. This review will discuss the potential impact of multi-target drug approach on various complex diseases with focus on malaria, tuberculosis (TB), diabetes and neurodegenerative diseases as the main representatives of multifactorial diseases. We will also discuss alternative ideas to solve the current problems bearing in mind the fourth industrial revolution on drug discovery.

Keywords: diabetes; malaria; multi-target drugs; tuberculosis and drug discovery.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
The discovery of anti-malaria drugs since 1820–1920s and their modes of action, and resistance. Most of these drugs depict the fact that their use and effectiveness had decreased dismally due to growing evidence of resistance and side effects.
Figure 2
Figure 2
Selected artemisinin-based combination treatment against P. falciparum.
Figure 3
Figure 3
Chemical structures of imeglimin and sotagliflozin.
Figure 4
Figure 4
Chemical structures of some of the plant-derived compounds with promising potential multi-target effect against diabetes.
Figure 5
Figure 5
Conceptual aspects of the reductionist approach (“Magic Bullet”) and polypharmacology.

References

    1. Medina-Franco JL, Giulianotti MA, Welmaker GS, Houghten RA. Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov Today. 2013;18(9–10):495–501. doi:10.1016/j.drudis.2013.01.008 - DOI - PMC - PubMed
    1. Ramsay RR, Popovic-Nikolic MR, Nikolic K, Uliassi E, Bolognesi ML. A perspective on multi-target drug discovery and design for complex diseases. Clin Transl Med. 2018;7(1). doi:10.1186/s40169-017-0181-2 - DOI - PMC - PubMed
    1. Brasnyó P, Molnár GA, Mohás M, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106(3):383–389. doi:10.1017/S0007114511000316 - DOI - PubMed
    1. Colín-Lozano B, Estrada-Soto S, Chávez-Silva F, et al. Design, synthesis and in combo antidiabetic bioevaluation of multitarget phenylpropanoic acids. Molecules. 2018;23(2):1–16. doi:10.3390/molecules23020340 - DOI - PMC - PubMed
    1. Qaseem A, Barry MJ, Humphrey LL, et al. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(4):279–290. doi:10.7326/M16-1860 - DOI - PubMed

MeSH terms